Astex Pharmaceuticals

Science Minister Vallance yesterday visited semiconductors and life sciences firms in Cambridgeshire, following his appointment as Oxford-Cambridge Innovation Champion

This spring, Astex, a world-leading innovative drug discovery and development company, took part in the BIA Global 850 Challenge for Kidney Research UK. They split into two teams, Astex C (for Corporate) and Astex A (because “A sounds better than B”) and began their journey to reach 850! Throughout the challenge both Astex teams dominated the leaderboard, maintaining first and second place in terms of both distance covered and money raised. Read about Astex A’s experience participating in the #850Challenge.

This spring, Astex, a world leading innovative drug discovery and development company, took part in the BIA Global 850 Challenge for Kidney Research UK. They split into two teams, Astex C (for Corporate) and Astex A (because “A sounds better than B”) and began their journey to reach 850! Throughout the challenge both Astex teams dominated the leaderboard, maintaining first and second place in terms of both distance covered and money raised. Read about Astex C’s experience participating in the #850Challenge.

Michelle Jones appointed as President and Gianni Chessari appointed as CSO.

Good to see support for BIA agendas in government messaging as we continue to push for pension fund reform, attracting the best global talent, UK manufacturing resilience and addressing the challenges of scaling.

Mosaic Therapeutics, Ltd, a targeted oncology therapeutics company dedicated to resolving cancer’s complexity with new combination therapies, announced the in-licensing of two clinical-stage oncology programs.

Astex Pharmaceuticals announced today that it will make five key data presentations at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics, 23rd-25th October 2024, Barcelona, Spain.